Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 15.8% from a year ago
Total assets stood at $553.6M at the end of Q1 FY2026, up 15.8% from a year earlier and up 28.4% from the prior quarter. Over 3 fiscal years it compounded at +300.6% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +15.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 430.99M USD
- Year-over-year change
- -24.3%
- 3-year CAGR
- +300.6%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 430.99M | -24.3% |
| FY2024 | 2024-12-31 | 569.2M | +143.3% |
| FY2023 | 2023-12-31 | 233.98M | +3390.7% |
| FY2022 | 2022-12-31 | 6.7M | — |
Total Assets vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 total assets of $553.6M is the highest of the 6 companies compared; the peer median is $205.17M.
- Its year-over-year change of +15.8% is the 3rd highest of 6, against a peer median of -3.0%.
- Over three fiscal years its annual growth of +300.6% compares with a peer median of +3.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $553.6M | +15.8% | +300.6% |
| Mar 2026 | $402.98M | -30.5% | -7.2% | |
| Mar 2026 | $217.87M | -3.0% | -3.9% | |
| Mar 2026 | $205.17M | +56.1% | +3.2% | |
| Mar 2026 | $199.13M | +3223.2% | +66.8% | |
| Mar 2026 | $58.86M | -36.7% | +21.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — |
| Peer median (excluding BCAX) | $205.17M | -3.0% | +3.2% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.